David Stefanich

WaiveDx is a healthcare technology company at the forefront of diagnostics, genetics, and AI. We integrate CLIA-waived point-of-care tools with proprietary molecular testing and AI-driven platforms to deliver fast, accurate, and personalized care across clinical, legal, and wellness sectors. Our portfolio includes WellGenx, Waive IQ, NeuDefense, Velisce, and Precision Diagnostics—each focused on advancing outcomes in behavioral health, pharmacogenetics, supplementation, and clinical trials. With proprietary assets like Nymara™, PredictIQ™ and Synapta™, Velisce™, and a track record of regulatory success, WaiveDX empowers labs, providers, and government partners across the U.S. to scale with confidence.

We seek to partner with African nations, international agencies, and the private sector to build a state-of-the-art pharmaceutical product development and manufacturing facility as well as a secure distribution network for improving patients’ access to affordable and high-quality medicines.

Rymedi's vision is to revolutionize access to precision health, connecting people across the globe to personalized care with digital workflows and data automation for patient testing, treatment and monitoring. With our secure & scalable platform, we streamline the transfer of health records to remove barriers between patients and providers. Our blockchain-enabled platform is comprised of simple solutions that empower health workers and patients to improve the quality and efficiency of care. We securely link the patient, provider, institution, employer, and lab, creating a marketplace of health solutions with each module optimized for a client’s unique needs.

Blockchain in Healthcare Global ("BiHG"​) is a new trade association launching in Q4 2018, formed under the IEEE ISTO (see https://ieee-isto.org/) by a multidisciplinary team of industry leaders in blockchain and healthcare. Our mission is to mitigate risks and barriers to adoption of blockchain and converging innovations (AI, IoMT, etc.) in healthcare and the life and social sciences while advancing progress in scientific replicability, medical ethics, human rights, and global inclusion.

- Chief Technology Officer – Bright Path Pharmaceuticals – Modular Pharmaceutical Manufacturer - Director IT – Bestco Pharmaceuticals - OTC Pharmaceutical Manufacturer – cGMP/CFR 21 - Compliance Auditor – Envision – Medical Device CFR 510/820 “The BRIDGE - Business Consortium” provides leading-edge industry expertise in Manufacturing, Transportation & Pharmaceutical Device development (IoT), Pharmaceutical Manufacturing and Supply (cGMP), and the M&A activities.

• Deliver integrated Service offerings within the NA trucking market that align with our Global and North America market opportunities. • Ensure our operating costs align well with our growth targets in North America to ensure profitability is being delivered within the segment. • Provide strategic and visionary input into our segments 5-7 plan matching our customers expectations while continuing to be leaders and innovators with the Transportation segment. • Creating new businesses Services partnerships through structuring commercial transactions, leveraging market leadership, and building out a portfolio of agile composite business services

Information Technology Member of the IT leadership committee and drove Joint Venture/Acquisition integration activities effectively delivering IT functionality necessary to support our Global Operations including MFG, MES, Engineering, and Embedded Vehicle Electronics; by tactically aligning 10 direct, 204 indirect reports, as well as off shore contractors. Integrated several MFG ERP Global initiatives in Australia, Brazil, North America, South Africa and Luxemburg Product Development Work closely with Product Leads to define performance metrics for our growing Global Engineering while ensuring the Operational TCO is delivered below projections. Define the evolving product structure to commonize across Vehicle and Powertrain through the adoption of design standards, and attribute based design while embracing the uniqueness and market driven direction of our product portfolio